Dtsch Med Wochenschr 2011; 136(36): 1790-1795
DOI: 10.1055/s-0031-1286104
Übersicht | Review article
Gastroenterologie
© Georg Thieme Verlag KG Stuttgart · New York

Helicobacter pylori: Infektion mit lokalen Komplikationen und systemischen Auswirkungen

Helicobacter pylori: an infection with local complications and systemic effectsM. Selgrad1 , J. Bornschein1 , P. Malfertheiner1
  • 1Klinik für Gastroenterologie, Hepatologie und Infektiologie, Otto-von-Guericke-Universität Magdeburg
Further Information

Publication History

eingereicht: 27.6.2011

akzeptiert: 18.8.2011

Publication Date:
31 August 2011 (online)

Literatur

  • 1 Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts.  Gut. 2001;  49 347-353
  • 2 Abdullahi M, Annibale B, Capoccia D. et al . The eradication of Helicobacter pylori is affected by body mass index (BMI).  Obes Surg. 2008;  18 1450-1454
  • 3 Anderson H R. Prevalence of asthma.  BMJ. 2005;  330 1037-1028
  • 4 Arnold D M, Bernotas A, Nazi I. et al . Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection.  Haematologica. 2009;  94 850-856
  • 5 Arslan E, Atilgan H, Yavasoglu I. The prevalence of Helicobacter pylori in obese subjects.  Eur J Intern Med. 2009;  20 695-697
  • 6 Asaka M, Kato M, Takahashi S. et al . Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition.  Helicobacter. 2010;  15 1-20
  • 7 Bago J, Majstorovic K, Belosic-Halle Z. et al . Antimicrobial resistance of H. pylori to the outcome of 10-days vs. 7-days moxifloxacin based therapy for the eradication.  Ann Clin Microbiol Antimicrob. 2010;  9 13
  • 8 Blaser M J, Chen Y, Reibman J. Does Helicobacter pylori protect against asthma and allergy?.  Gut. 2008;  57 561-567
  • 9 Bornschein J, Selgrad M, Warnecke M. et al . H. pylori infection is a key risk factor for proximal gastric cancer.  Dig Dis Sci. 2010;  55 3124-3131
  • 10 Bourke B, Ceponis P, Chiba N. et al . Canadian Helicobacter Study Group Consensus Conference: Update on the approach to Helicobacter pylori infection in children and adolescents – an evidence-based evaluation.  Can J Gastroenterol. 2005;  19 399-408
  • 11 Caselli M, Zullo A, Maconi G. et al . „Cervia II Working Group Report 2006”: guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy.  Dig Liver Dis. 2007;  39 782-789
  • 12 Cassaro M, Rugge M, Gutierrez O. et al . Topographic patterns of intestinal metaplasia and gastric cancer.  Am J Gastroenterol. 2000;  95 1431-1438
  • 13 Chey W D, Wong B C. American College of Gastroenterology guideline on the management of Helicobacter pylori infection.  Am J Gastroenterol. 2007;  102 1808-2185
  • 14 Codolo G, Mazzi P, Amedei A. et al . The neutrophil-activating protein of Helicobacter pylori down-modulates Th2 inflammation in ovalbumin-induced allergic asthma.  Cell Microbiol. 2008;  10 2355-2363
  • 15 D’Elios M M, Codolo G, Amedei A. et al . Helicobacter pylori, asthma and allergy.  FEMS Immunol Med Microbiol. 2009;  56 1-8
  • 16 de Vries A C, Kuipers E J. Helicobacter pylori infection and nonmalignant diseases.  Helicobacter. 2010;  15 Suppl 1 29-33
  • 17 de Vries A C, Kuipers E J, Rauws E A. Helicobacter pylori eradication and gastric cancer: when is the horse out of the barn?.  Am J Gastroenterol. 2009;  104 1342-1345
  • 18 de Vries A C, van Grieken N C, Looman C W. et al . Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands.  Gastroenterology. 2008;  134 945-952
  • 19 MF, Cavallaro L G, Scarpignato C. ‘Rescue’ therapies for the management of Helicobacter pylori infection.  Dig Dis. 2006;  24 113-130
  • 20 Dore M P, Graham D Y, Mele R. et al . Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection.  Am J Gastroenterol. 2002;  97 857-860
  • 21 Ekstrom A M, Held M, Hansson L E. et al . Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection.  Gastroenterology. 2001;  121 784-791
  • 22 Essa A S, Kramer J R, Graham D Y. et al . Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing „concomitant therapy” versus triple therapy for Helicobacter pylori eradication.  Helicobacter. 2009;  14 109-118
  • 23 Ferrara M, Capozzi L, Russo R. Effect of Helicobacter pylori eradication on platelet count in children with chronic idiopathic thrombocytopenic purpura.  Hematology. 2009;  14 282-285
  • 24 Fischbach W, Malfertheiner P, Hoffmann J C. et al . S3-guideline „helicobacter pylori and gastroduodenal ulcer disease” of the German society for digestive and metabolic diseases (DGVS) in cooperation with the German society for hygiene and microbiology, society for pediatric gastroenterology and nutrition e. V., German society for rheumatology, AWMF-registration-no. 021 / 001.  Z Gastroenterol. 2009;  47 1230-1263
  • 25 Fock K M, Katelaris P, Sugano K. et al . Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection.  J Gastroenterol Hepatol. 2009;  24 1587-600
  • 26 Fuccio L, Minardi M E, Zagari R M. et al . Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication.  Ann Intern Med. 2007;  147 553-562
  • 27 Fuccio L, Zagari R M, Eusebi L H. et al . Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer?.  Ann Intern Med. 2009;  151 121-128
  • 28 Fukase K, Kato M, Kikuchi S. et al . Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial.  Lancet. 2008;  372 392-397
  • 29 Gasbarrini A, Franceschi F, Tartaglione R. et al . Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori.  Lancet. 1998;  352 878
  • 30 Gatta L, Vakil N, Leandro G. et al . Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.  Am J Gastroenterol. 2009;  104 3069-3079
  • 31 Gene E, Calvet X, Azagra R. et al . Triple vs quadruple therapy for treating Helicobacter pylori infection: an updated meta-analysis.  Aliment Pharmacol Ther. 2003;  18 543-544
  • 32 Huang X, Qu X, Yan W. et al . Iron deficiency anaemia can be improved after eradication of Helicobacter pylori.  Postgrad Med J. 2010;  86 272-278
  • 33 Kamada T, Hata J, Sugiu K. et al . Clinical features of gastric cancer discovered after successful eradication of Helicobacter pylori: results from a 9-year prospective follow-up study in Japan.  Aliment Pharmacol Ther. 2005;  21 1121-1126
  • 34 Karlsson E A, Beck M A. The burden of obesity on infectious disease.  Exp Biol Med. 2010;  235 1412-1424
  • 35 Kodama M, Kitadai Y, Ito M. et al . Immune response to CagA protein is associated with improved platelet count after Helicobacter pylori eradication in patients with idiopathic thrombocytopenic purpura.  Helicobacter. 2007;  12 36-42
  • 36 Liou J M, Lin J T, Chang C Y. et al . Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design.  Gut. 2010;  59 572-578
  • 37 Mahachai V, Sirimontaporn N, Tumwasorn S. et al . Sequential therapy in clarithromycin-sensitive and -resistant Helicobacter pylori based on polymerase chain reaction molecular test.  J Gastroenterol Hepatol. 2011;  26 825-828
  • 38 Malfertheiner P, Bazzoli F, Delchier J C. et al . Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy.  Lancet. 2011;  377 905-913
  • 39 Malfertheiner P, Megraud F, O’Morain C. et al . Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.  Gut. 2007;  56 772-781
  • 40 Malfertheiner P, Selgrad M. Helicobacter pylori infection and current clinical areas of contention.  Curr Opin Gastroenterol. 2010;  26 618-623
  • 41 Malfertheiner P, Sipponen P, Naumann M. et al . Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique.  Am J Gastroenterol. 2005;  100 2100-2115
  • 42 Megraud F. Helicobacter pylori and antibiotic resistance.  Gut. 2007;  56 1502
  • 43 Moayyedi P. Should triple therapy for Helicobacter pylori eradication be prescribed for 1 week or 2 weeks?.  Nat Clin Pract Gastroenterol Hepatol. 2007;  4 596-597
  • 44 Nista E C, Candelli M, Zocco M A. et al . Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection.  Aliment Pharmacol Ther. 2005;  21 1241-1247
  • 45 Ohkusa T, Fujiki K, Takashimizu I. et al . Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated.  Ann Intern Med. 2001;  134 380-386
  • 46 Robinson K, Kenefeck R, Pidgeon E L. et al . Helicobacter pylori-induced peptic ulcer disease is associated with inadequate regulatory T cell responses.  Gut. 2008;  57 1375-1385
  • 47 Romano M, Cuomo A, Gravina A G. et al . Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication.  Gut. 2010;  59 1465-1470
  • 48 Rugge M, Meggio A, Pennelli G. et al . Gastritis staging in clinical practice: the OLGA staging system.  Gut. 2007;  56 631-636
  • 49 Sarker S A, Mahmud H, Davidsson L. et al . Causal relationship of Helicobacter pylori with iron-deficiency anemia or failure of iron supplementation in children.  Gastroenterology. 2008;  135 1534-1542
  • 50 Strachan D P. Hay fever, hygiene, and household size.  BMJ. 1989;  299 1259-1260
  • 51 Suzuki T, Matsuo K, Ito H. et al . Smoking increases the treatment failure for Helicobacter pylori eradication.  Am J Med. 2006;  119 217-224
  • 52 Take S, Mizuno M, Ishiki K. et al . Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases.  J Gastroenterol. 2007;  42 Suppl 17 21-27
  • 53 Uemura N, Mukai T, Okamoto S. et al . Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer.  Cancer Epidemiol Biomarkers Prev. 1997;  6 639-642
  • 54 Uemura N, Okamoto S, Yamamoto S. et al . Helicobacter pylori infection and the development of gastric cancer.  N Engl J Med. 2001;  345 784-789
  • 55 Weigt J, Malfertheiner P. Influence of Helicobacter pylori on gastric regulation of food intake.  Curr Opin Clin Nutr Metab Care. 2009;  12 522-525
  • 56 Wong B C, Lam S K, Wong W M. et al . Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China.  JAMA. 2004;  291 187-194
  • 57 Wu D C, Hsu P I, Wu J Y. et al . Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection.  Clin Gastroenterol Hepatol. 2010;  8 36-41

Prof. Dr. Dres. h. c. Peter Malfertheiner

Klinik für Gastroenterologie, Hepatologie und Infektiologie
Otto-von-Guericke-Universität

Leipziger Str. 44

39120 Magdeburg

Phone: 0391/6713100

Fax: 0391/6713105

Email: peter.malfertheiner@med.ovgu.de